Optinose Stock Price, News & Analysis

Optinose (NASDAQ:OPTN) announced that its XHANCE treatment met both co-primary endpoints in the ReOpen1 clinical trial for chronic sinusitis. The trial involved 332 patients and demonstrated statistically significant improvements in both symptom scores and CT scan results compared to a placebo. Given the absence of FDA-approved drug treatments for the estimated 30 million adults suffering from chronic sinusitis, this outcome is a potential breakthrough. Top-line results from the second trial, ReOpen2, are expected in Q2 2022.

Optinose (NASDAQ:OPTN) will report its Q4 2021 financial results and corporate updates on March 8, 2022, before market open. A conference call will follow at 8:00 a.m. ET for discussions on the results. The company’s CEO, Peter Miller, is set to present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:10 p.m. ET. Interested parties can join the call via telephone or access a live webcast on the company’s website. A replay of both the conference call and the webcast will be available for 60 days.

Optinose (NASDAQ:OPTN) announced the appointment of Drs. Eric Bednarski and Kyle Dempsey to its Board of Directors. Both new directors bring extensive healthcare investment experience from MVM Partners, a growth equity firm. Eric, a seasoned investor, previously held positions at Advent Healthcare Ventures and Silicon Valley Bank. Kyle has a background in consulting at Bain & Company, emphasizing healthcare commercialization. Chairman Joe Scodari expressed confidence in their contributions, highlighting their expertise in global healthcare investments.

Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, announced that CEO Peter Miller will present a company overview at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. A pre-recorded fireside chat is available on their website, with 1x1 meetings set for November 30. The webcast will be accessible for 30 days post-event. For more information, visit Optinose.

OptiNose (NASDAQ:OPTN) announced the grant of non-qualified stock options to six new employees as an employment inducement. A total of 53,500 shares were awarded, with exercise prices reflecting the stock's closing prices on their respective grant dates ($2.64 and $1.59). The options, which have a 10-year term, will vest over four years, with 25% vesting on the first anniversary of the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention and incentivize performance.

Optinose (NASDAQ:OPTN) has successfully closed its underwritten public offering of 28,750,000 shares at $1.60 per share, raising gross proceeds of $46.0 million. The offering included the full exercise of the underwriters' option for an additional 3,750,000 shares. The net proceeds will primarily fund working capital, general corporate purposes, and the commercialization and clinical development of XHANCE for chronic sinusitis. The offering followed a shelf registration statement filed with the SEC.

Optinose (NASDAQ:OPTN) has priced an underwritten public offering of 25 million shares at $1.60 per share, generating $40 million in gross proceeds before expenses. The offering is expected to close around November 18, 2021, pending customary conditions. Proceeds will fund working capital and support XHANCE's commercialization and clinical development for chronic sinusitis. Additionally, underwriters have a 30-day option to purchase 3.75 million shares at the offering price.

Optinose (NASDAQ:OPTN) announces plans for an underwritten public offering of common stock. All shares will be sold by the company, with an option for underwriters to purchase an additional 15% within 30 days. Proceeds will be used for working capital, general corporate purposes, and to support the commercialization and clinical development of XHANCE. The public offering price is yet to be determined and is subject to market conditions.

Optinose (NASDAQ:OPTN) reported a strong third quarter 2021 with XHANCE net revenue of $22 million, a 41% increase from Q3 2020. Total prescriptions rose 25% to 86,300, while new prescriptions increased by 22%. The company completed enrollment in pivotal trials for chronic sinusitis, expanding the potential patient base from 1 million to 3 million.

However, full-year 2021 net revenue guidance was reduced to $71-$75 million from at least $80 million. Operating expenses are projected at $132-$137 million. Cash reserves stand at $84.2 million.